Furthermore, the DNA methyltransferase inhibitor 5-azacytidine (5-azaC) has been shown to be an effective treatment for patients with high-risk MDS and secondary AML142,143, indicating that aberrant DNA methylation plays a crucial part in MDS development and progression. cell reprogramming and regenerative medicine. Eukaryotic chromatin contains a wealth of information required for the growth and development of a multicellular organism. This information is not only stored genetically in the DNA sequence itself but also epigenetically through DNA methylation and post-translational modifications of histone proteins1,2. Although every nucleotide in the genome has the potential to be transcribed3, the presence or absence of specific epigenetic marks influences gene Mevalonic acid expression, resulting in a transcriptional programme that specifies for a particular cell type. For example, in embryonic stem (ES) cells, active gene expression marks are found at pluripotent genes and repressive marks are found at lineage-specific genes. Thus, different cell types can be defined by their epigenetic and gene expression profiles. During development, these transcriptional programmes undergo dynamic changes that ultimately lead to the production of distinct cell types and tissues that make up an organism. Accommodating such a transcriptional programme requires an epigenome that is both dynamic and flexible. Furthermore, the diversity of genetic material to be regulated necessitates the use of marks corresponding to short-term and long-term epigenetic memory, depending on the transcriptional requirements of the cell (as well as those Mevalonic acid of future generations). Developmental genes that are needed during the later stages of development are transiently Rabbit Polyclonal to E2F6 held in a repressed state during early development. This is achieved through short-term epigenetic marks such as histone modifications, which can be removed before or within a few cell divisions. By contrast, other regions of the genome are marked with epigenetic information that is stably maintained and heritable after many cell divisions. For example, imprinted genes, transposons and the inactive X chromosome Mevalonic acid require long-term silencing that is sustained throughout the development and lifespan of an organism. This is generally achieved by DNA methylation, an epigenetic mark that refers to the addition of a methyl group to the fifth carbon of base C. Because DNA methylation provides heritable, long-term silencing that is crucial for an organism, aberrant DNA methylation has been associated with cancer, imprinting-related diseases and psychiatric disorders4-7. In mammals, DNA methylation occurs predominantly in the context of CpG (C followed by G) dinucleotides, whereas DNA methylation in plants can occur at C bases in diverse sequence contexts8. The enzymes responsible for this modification, DNA methyltransferases (DNMTs), are well characterized and conserved in mammals and plants8. DNMTs fall under two categories:de novoand maintenance9. Patterns of DNA methylation are initially established by thede novoDNA methyltransferasesDNMT3AandDNMT3Bduring the blastocyst stage of embryonic development10,11(FIG. 1). These methyl marks are then faithfully maintained during cell divisions through Mevalonic acid the action of the maintenance methyltransferase,DNMT1, which has a preference for hemi-methylated DNA12-14. Both the establishment and maintenance of DNA methylation patterns are crucial for development as mice deficient in DNMT3B or DNMT1 are embryonic lethal11,15and DNMT3A-null mice die by 4 weeks of age11. == Figure 1. Mechanisms of DNa methylation and demethylation. == During early development, methylation patterns are initially established by thede novoDNA methyltransferases DNMT3A and DNMT3B. When DNA replication and cell division occur, these methyl marks are maintained in daughter cells by the Mevalonic acid maintenance methyltransferase, DNMT1, which has a preference for hemi-methylated DNA. If DNMT1 is inhibited or absent when the cell divides, the newly synthesized strand of DNA will not be methylated and successive rounds of cell division will result in passive demethylation. By contrast, active demethylation can occur through the enzymatic replacement of 5-methylcytosine (5meC) with C. Although DNA methylation has been viewed as a stable epigenetic mark, studies in the past decade have revealed that this modification is not as static as once thought. In fact, loss of DNA methylation, or DNA demethylation, has been observed in specific contexts (see below) and can occur through active or passive mechanisms (FIG. 1). Active DNA demethylation is the enzymatic process that results in the removal of the methyl group from 5-methylcytosine (5meC) by breaking a carbon-carbon bond. By contrast, passive DNA demethylation refers to the loss of the methyl group from 5meC when DNMT1 is inhibited or absent during successive rounds of DNA replication. whereas passive DNA demethylation is generally understood and accepted, the subject of active DNA demethylation has been controversial16. In this Review, we explore what is known about active DNA demethylation and the disputes that are embedded in this field. First, we describe the contexts in which DNA demethylation has been observed and discuss the evidence that supports an active mechanism. we then present the many enzymes that have been proposed to carry out active DNA demethylation. we conclude.
Categories:Retinoid X Receptors